CarrynM(Ensrude)AndersonMD
Radiation Oncology • Iowa City, IAAssistant Professor, Radiation Oncology, University of Iowa College of Medicine
Dr. Anderson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
01614 Pfpw
Iowa City, IA 52242Phone+1 319-353-8836Fax+1 319-356-1530
Education & Training
Cleveland Clinic FoundationResidency, Radiation Oncology, 2003 - 2008
University of Texas Medical Branch School of MedicineClass of 2003
Certifications & Licensure
IA State Medical License 2008 - 2025
OH State Medical License 2003 - 2025- American Board of Radiology Radiation Oncology
Clinical Trials
- [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Start of enrollment: 2012 Oct 01
- A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme Start of enrollment: 2013 Apr 01
- Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I Start of enrollment: 2014 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 173 citationsKetogenic diets as an adjuvant cancer therapy: History and potential mechanism.Bryan G. Allen, Sudershan K. Bhatia, Carryn M. Anderson, Julie M. Eichenberger-Gilmore, Zita A. Sibenaller
Redox Biology. 2014-01-01 - 9 citationsAggressive Salivary Malignancies at Early Stage: Outcomes and Implications for Treatment.Robert W. Eppsteiner, Jonathan W Fowlkes, Carryn M. Anderson, Robert A. Robinson, Nitin A. Pagedar
The Annals of Otology, Rhinology, and Laryngology. 2017-05-05 - 15 citationsKetogenic Diet with Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma: Preclinical and Phase 1 Trial Results.Daniel C. Ma, Carryn M. Anderson, Samuel N. Rodman, Visarut Buranasudja, Michael L. McCormick
Radiation Research. 2021-06-04
Press Mentions
Avasopasem Promising for Severe Oral Mucositis During IMRT for Locally Advanced Head and Neck CancersJune 4th, 2022
Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral MucositisMarch 1st, 2020
Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual MeetingJune 29th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
